MRNA vs VRTX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MRNA · Moderna$254.19 ▲ 5.27%
VRTX · Vertex Pharmaceuticals$547.09 ▲ 0.85%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MRNA +926.6%
- VRTX +29.9%
Head to head
| Metric | MRNA | VRTX |
|---|---|---|
| Price | $254.19 | $547.09 |
| Change today | ▲ 5.27% | ▲ 0.85% |
| Market cap | $101.48B | $138.71B |
| Return, 3 months | +325.0% | +4.4% |
| Return, year to date | +762.0% | +20.7% |
| Return, 1 year | +935.8% | +33.6% |
| P/E (TTM) | – | 35.2 |
| P/B | 15.0 | 6.6 |
| P/E percentile vs own 5y | 1st | 97th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +4.4% | +12.5% |
| Net profit growth (YoY) | +5.2% | +6.5% |
| Gross margin | 22.8% | 86.0% |
| Operating margin | -150.2% | 37.9% |
| Net margin | -142.6% | 35.0% |
| Return on equity | -39.0% | 23.5% |
| Analyst target vs. price | -42.3% | +14.4% |
| Analyst buy share | 15% | 95% |
| RSI (14) | 64 | 58 |
| 30-day volatility | 101.4% | 32.0% |
| Max drawdown, 1 year | -34.2% | -15.2% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VRTX is the largest of the group by market value.
- MRNA has returned the most over the past year.
- VRTX is growing revenue fastest.
- VRTX keeps the most profit per dollar of sales.
- VRTX has been the calmest stock over the last 30 days.